Multiple myeloma market will more than double to $5.3 billion in 2018

The multiple myeloma drug market will more than double from $2.1 billion in 2008 to $5.3 billion in 2018 in the USA, France, Germany, Italy, Spain, the UK and Japan, according to a new report from advisory firm Decision Resources.

The Pharmacor 2010 findings from the topic titled Multiple Myeloma reveal that market growth will be driven by increased use of Celgene's Revlimid (lenalidomide) in the first-line setting and the launches of several premium-priced emerging therapies, most notably Celgene's pomalidomide and Onyx Pharmaceuticals' carfilzomib. Currently, the multiple myeloma market is dominated by Revlimid, Millennium Pharmaceuticals/Janssen-Cilag/Janssen's Velcade (bortezomib) and Celgene/Fujimoto Seiyaku's Thalomid/Thaled (thalidomide).

"Carfilzomib and pomalidomide are the most promising emerging therapies in development, owing to their efficacy and tolerability," said Decision Resources analyst Andrew Merron. "Carfilzomib and pomalidomide will compete with Velcade and Revlimid, respectively, although they will struggle to attain the same market share as these well-established agents."